NCT07088107

Brief Summary

Stroke is a type of cerebrovascular disease, and the primary characteristic of post-stroke brains is pathological changes in cerebral hemodynamics. Therefore, hemodynamic signals may provide straightforward information for guiding post-stroke neuromodulation therapy. Transcranial magnetic stimulation (TMS), a non-invasive neurostimulation modality, has been extensively used in post-stroke rehabilitation. However, current TMS-based neuromodulation therapy demonstrates a large treatment response variability due to its open-loop nature. To address this challenge, the research team will develop a novel form of closed-loop neurofeedback interfaces which controls the timing of TMS pulses precisely based on neural biomarkers from functional near-infrared spectroscopy (fNIRS) and test the accuracy of the adaptive neurofeedback system in healthy adults. After establishing the TMS-based neurofeedback interface, a proof-of-concept study enrolling postacute stroke patients will be performed to evaluate the efficacy of the TMS neurofeedback interface in enhancing motor control of the hemiplegic upper extremity and cortical excitability of the ipsilesional motor cortex. These findings will verify whether the proposed fNIRS-controlled TMS neurofeedback interface can be clinically feasible as a form of post-stroke neuromodulation therapy. Additionally, the results will significantly contribute to the scientific understanding of how neuromodulation improves hemodynamic signals in a closed-loop manner, thereby enhancing functional recovery in poststroke survivors.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P75+ for not_applicable stroke

Timeline
33mo left

Started Aug 2025

Longer than P75 for not_applicable stroke

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress22%
Aug 2025Dec 2028

First Submitted

Initial submission to the registry

July 20, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 28, 2025

Completed
4 days until next milestone

Study Start

First participant enrolled

August 1, 2025

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2028

Last Updated

March 3, 2026

Status Verified

July 1, 2025

Enrollment Period

2.4 years

First QC Date

July 20, 2025

Last Update Submit

March 1, 2026

Conditions

Keywords

StrokeNeurofeedbackBrain Stimulation

Outcome Measures

Primary Outcomes (1)

  • Motor evoked potential

    Motor Evoked Potentials (MEPs) are electrical signals generated by stimulating the motor cortex and recorded from the peripheral muscle (e.g., a hand muscle). This is a measure of corticospinal excitability.

    Baseline

Study Arms (2)

functional near-infrared spectroscopy (fNIRS)-triggered TMS

EXPERIMENTAL

The TMS will be triggered based on individualized fNIRS signals from the participants. Specifically, the TMS will be triggered during high-excitability phase of fNIRS hemodynamic response during motor imagination.

Device: fNIRS-triggered TMS

TMS

ACTIVE COMPARATOR

The TMS will be triggered by the operator according to a pre-defined protocol

Device: fNIRS-triggered TMS

Interventions

The firing of TMS will be triggered according to fNIRS signal intensity.

TMSfunctional near-infrared spectroscopy (fNIRS)-triggered TMS

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participants who meet the following criteria will be included:
  • Diagnosed with ischemic subcortical stroke, with stroke onset≥6 months.
  • Age between 18 and 80 years.
  • Residual upper limb functions between levels 2-7 in the FTHUE.
  • Capable of providing informed written consent.
  • Capable of reading and communicating with Chinese.

You may not qualify if:

  • Patients who meet any of the following criteria will be excluded:
  • any contraindications to TMS (screened by the safety checklist by Rossi).
  • signs of cognitive impairment, with a Montreal cognitive assessment score\<21/22 out of 30.
  • any moderate-to-severe chronic illness, such as uncontrolled hypertension, heart disease or renal failure.
  • Healthy participants should be aged between 18 and 80, with no known history of neurological diseases. They should not have any moderate-to-severe chronic illness, such as uncontrolled hypertension, heart disease or renal failure.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Hong Kong Polytechnic University

Hong Kong, 000000, Hong Kong

NOT YET RECRUITING

Hong Kong Polytechnic University - Brain Stimulation Laboratory

Hong Kong, Hong Kong

RECRUITING

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Central Study Contacts

Jack Jiaqi Zhang, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 20, 2025

First Posted

July 28, 2025

Study Start

August 1, 2025

Primary Completion (Estimated)

December 30, 2027

Study Completion (Estimated)

December 30, 2028

Last Updated

March 3, 2026

Record last verified: 2025-07

Locations